

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Raltegravir Pediatric Granules Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Serious eye damage, Category 1	H318: Causes serious eye damage.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H318 Causes serious eye damage.
H335 May cause respiratory irritation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

H361d Suspected of damaging the unborn child.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P261 Avoid breathing dust.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Raltegravir

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Raltegravir	871038-72-1	Eye Dam. 1; H318 Repr. 2; H361d STOT SE 3; H335	>= 20 - < 30

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Ammonium hydroxide	1336-21-6 215-647-6 007-001-01-2	Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 Aquatic Acute 1; H400 Aquatic Chronic 2; H411 EUH071 M-Factor (Acute aquatic toxicity): 1 specific concentra- tion limit STOT SE 3; H335 >= 5 % Acute toxicity esti- mate Acute oral toxicity: 350 mg/kg	>= 0,1 - < 0,25
--------------------	--	--	-----------------

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes serious eye damage.
May cause respiratory irritation.
Suspected of damaging the unborn child.

Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

- Advice on safe handling : Avoid breathing dust.
Do not swallow.
Do not get in eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

- Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

	Dust	5 mg/m ³ Value type (Form of exposure): TWA (respirable dust) Basis: FOR-2011-12-06-1358
		10 mg/m ³ Value type (Form of exposure): TWA (total dust) Basis: FOR-2011-12-06-1358

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version 7.0 Revision Date: 13.11.2025 SDS Number: 20456-00028 Date of last issue: 09.05.2025
Date of first issue: 09.10.2014

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m ³) (OEB 1)	Internal

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Raltegravir	Fresh water	0,4 mg/l
	Marine water	0,4 mg/l
Ammonium hydroxide	Fresh water	0,001 mg/l
	Freshwater - intermittent	0,008 mg/l
	Marine water	0,001 mg/l
	Soil	0,022 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection :
Material : Chemical-resistant gloves
- Skin and body protection : Work uniform or laboratory coat.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to NS EN 143
- Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- Physical state : solid
- Form : powder
- Colour : off-white
- Odour : odourless
- Odour Threshold : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Relative density	:	No data available
Relative vapour density	:	No data available
Particle characteristics		
Particle size	:	No data available

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Raltegravir:

Acute oral toxicity : LD50 (Mouse, male and female): > 2.000 mg/kg

Ammonium hydroxide:

Acute oral toxicity : LD50 (Rat): 350 mg/kg

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Components:

Raltegravir:

Species	: Rabbit
Result	: No skin irritation

Ammonium hydroxide:

Species	: Rabbit
Result	: Corrosive after 3 minutes to 1 hour of exposure
Remarks	: Based on national or regional regulation.

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Raltegravir:

Species	: Bovine cornea
Result	: Severe irritation

Ammonium hydroxide:

Result	: Irreversible effects on the eye
Remarks	: Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Raltegravir:

Test Type	: Local lymph node assay (LLNA)
Species	: Mouse
Result	: negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Raltegravir:

Genotoxicity in vitro	: Test Type: reverse mutation assay Result: negative
	Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Test Type: Chromosomal aberration
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 475
Result: negative

Ammonium hydroxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Raltegravir:

Species : Mouse, male and female
Exposure time : 104 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 600 mg/kg body weight
Result: negative

Effects on foetal development : Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: $\geq$ 600 mg/kg body weight
Teratogenicity: LOAEL F1: 300 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Species: Rabbit
General Toxicity Maternal: NOAEL: $\geq$ 1.000 mg/kg body weight
Teratogenicity: NOAEL: $\geq$ 1.000 mg/kg body weight
Result: negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause respiratory irritation.

Components:

Raltegravir:

Exposure routes : Inhalation
Target Organs : Respiratory Tract
Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Raltegravir:

Species : Dog
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 371 d
Symptoms : Vomiting

Species : Rat
NOAEL : 30 mg/kg
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 189 d
Target Organs : Stomach

Species : Mouse
NOAEL : 50 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Stomach

Species : Rat
NOAEL : 50 mg/kg
LOAEL : 200 mg/kg
Application Route : Oral
Exposure time : 8 Weeks
Target Organs : Stomach

Aspiration toxicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Raltegravir:

Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Raltegravir:

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 3,8 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

	NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	: NOEC: 9,3 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 9,5 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Ammonium hydroxide:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 0,89 mg/l Exposure time: 96 h Test substance: Neutralised product
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 101 mg/l Exposure time: 48 h
M-Factor (Acute aquatic toxicity)	: 1
Toxicity to fish (Chronic toxicity)	: NOEC: 0,0135 mg/l Exposure time: 73 d Species: Oncorhynchus mykiss (rainbow trout) Test substance: Neutralised product
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0,961 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

Raltegravir:

Biodegradability	: Result: rapidly degradable Biodegradation: 50 % Exposure time: 9 d Method: OECD Test Guideline 302B
Stability in water	: Hydrolysis: < 10 %(5 d) Method: OECD Test Guideline 111

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

12.3 Bioaccumulative potential

Components:

Raltegravir:

Partition coefficient: n-octanol/water : log Pow: -0,328

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.4 Packing group

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA (Cargo)	: Not regulated as a dangerous good
IATA (Passenger)	: Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	: Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please
--	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.	:	Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

The components of this product are reported in the following inventories:

AICS	:	not determined
CA. DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H302	:	Harmful if swallowed.
H314	:	Causes severe skin burns and eye damage.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

H318	: Causes serious eye damage.
H335	: May cause respiratory irritation.
H361d	: Suspected of damaging the unborn child.
H400	: Very toxic to aquatic life.
H411	: Toxic to aquatic life with long lasting effects.
EUH071	: Corrosive to the respiratory tract.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Dam.	: Serious eye damage
Repr.	: Reproductive toxicity
Skin Corr.	: Skin corrosion
STOT SE	: Specific target organ toxicity - single exposure
FOR-2011-12-06-1358	: Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA	: Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09.05.2025
7.0	13.11.2025	20456-00028	Date of first issue: 09.10.2014

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Dam. 1	H318
Repr. 2	H361d
STOT SE 3	H335

Classification procedure:

Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN